Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Ivermectin Cream

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    9 result(s) found for: Ivermectin Cream. Displaying page 1 of 1.
    EudraCT Number: 2017-000157-40 Sponsor Protocol Number: RD.03.SPR.113322 Start Date*: 2017-06-15
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy comparison of Ivermectin 1% topical cream associated with Doxycycline 40 mg Modified release (MR) capsules versus Ivermectin 1% topical cream associated with Placebo in the treatment of s...
    Medical condition: severe Rosacea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001999-20 Sponsor Protocol Number: RD.03.SPR.40027 Start Date*: 2006-10-10
    Sponsor Name:Galderma Research & Development SNC
    Full Title: ASSESSMENT OF THE EFFICACY AND SAFETY OF THREE CONCENTRATIONS: 1%, 0.3%, 0.1% OF CD5024 CREAM ONCE DAILY AND CD5024 1% CREAM TWICE DAILY, VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM (RO...
    Medical condition: Patients with papulo-pustular rosacea
    Disease: Version SOC Term Classification Code Term Level
    9.0 10039218 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-004791-11 Sponsor Protocol Number: RD.03.SPR.40173CZ Start Date*: 2012-03-12
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy and safety of CD5024 1% cream versus metronidazole 0.75% cream in subjects with papulopustular rosacea over 16 weeks treatment, followed by a 36-week extension period
    Medical condition: Papulo Pustular Rosacea
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10039218 Rosacea PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) DE (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-000063-16 Sponsor Protocol Number: RD.03.SPR.109807 Start Date*: 2016-06-10
    Sponsor Name:Galderma R&D SNC
    Full Title: Efficacy and safety of CD5024 1% in acne vulgaris
    Medical condition: Acne vulgaris
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004858 10000519 Acne vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006673-91 Sponsor Protocol Number: RD.03.SPR.40051 Start Date*: 2008-07-04
    Sponsor Name:GALDERMA R&D SNC
    Full Title: A MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF CD5024 1% CREAM TREATMENT FOR UP TO 52 WEEKS IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA
    Medical condition: PATIENTS WITH PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Prematurely Ended) HU (Completed) IS (Prematurely Ended) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-003854-13 Sponsor Protocol Number: RD.03.SPR.40053 Start Date*: 2009-01-15
    Sponsor Name:GALDERMA R&D SNC
    Full Title: AN INVESTIGATOR BLIND PARALLEL GROUP VEHICLE CONTROL STUDY COMPARING THE EFFICACY AND SAFETY OF CD 5024 1% CREAM WITH METRONIDAZOLE 0.75% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 1...
    Medical condition: PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002679-29 Sponsor Protocol Number: RD.03.SPR.40064 Start Date*: 2008-07-04
    Sponsor Name:GALDERMA R&D SNC
    Full Title: Plasma Pharmacokinetics study of CD5024 1% cream in subjects with papulopustular rosacea
    Medical condition: PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-018319-13 Sponsor Protocol Number: RD.03.SPR.40106 Start Date*: 2010-08-17
    Sponsor Name:GALDERMA R&D SNC
    Full Title: A DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY ASSESSING THE ACTIVITY OF CD5024 1% CREAM IN SUBJECTS WITH PAPULOPUSTULAR ROSACEA OVER 12 WEEKS TREATMENT
    Medical condition: PATIENTS WITH PAPULOPUSTULAR ROSACEA
    Disease: Version SOC Term Classification Code Term Level
    9.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) FI (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2006-003156-37 Sponsor Protocol Number: RD.03.SPR.40037 Start Date*: 2006-10-13
    Sponsor Name:Galderma Research and Development SNC
    Full Title: AN EXPLORATORY STUDY TO EVALUATE RELAPSES FOLLOWING AN INITIAL 12 WEEKS DOSE-RANGE STUDY WITH CD5024 CREAM VERSUS ITS VEHICLE AND VERSUS METRONIDAZOLE 0.75% CREAM IN PAPULO-PUSTULAR ROSACEA – A 6 M...
    Medical condition: Subject who was successfully treated for his/her papulo-pustular rosacea in the initial study (Galderma Study: Eudract N°: 2006-001999-20/RD.03.SPR.40027)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039218 Rosacea LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:17:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA